(QGEN) Qiagen - Ratings and Ratios
Sample Prep Kits, Assays, PCR Instruments, NGS Products, Bioinformatics Software
Dividends
| Dividend Yield | 3.21% |
| Yield on Cost 5y | 3.29% |
| Yield CAGR 5y | % |
| Payout Consistency | 8.8% |
| Payout Ratio | 63.7% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 22.0% |
| Value at Risk 5%th | 35.1% |
| Relative Tail Risk | -3.08% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.42 |
| Alpha | 1.63 |
| CAGR/Max DD | 0.02 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.530 |
| Beta | 0.540 |
| Beta Downside | 0.464 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.98% |
| Mean DD | 11.13% |
| Median DD | 10.89% |
Description: QGEN Qiagen October 31, 2025
Qiagen N.V. (NYSE: QGEN) delivers “sample-to-insight” solutions that convert biological specimens into molecular data for diagnostics, research, and applied testing. Its product portfolio spans primary consumables (e.g., nucleic-acid stabilization kits, magnetic-bead purification), secondary consumables (purification kits, silica membranes), and a range of instruments for nucleic-acid extraction, quality control, and PCR/NGS workflows. The company also offers specialty assays-including interferon-γ release tests for TB, prenatal and sexually transmitted infection panels, and forensic STR kits-as well as software-as-a-service and custom genomic services for molecular diagnostics, academia, pharma, and industrial testing.
Key recent metrics (Q3 2024) show revenue of $1.28 bn, up 7 % YoY, driven primarily by a 12 % increase in the Molecular Diagnostics segment and a 9 % rise in the Research segment. R&D spending remains high at ~15 % of revenue, reflecting ongoing investment in NGS panels and digital-PCR platforms. Sector-wide, the life-sciences tools market is expanding at a 6-7 % CAGR, propelled by the global rollout of infectious-disease testing, the growing adoption of companion-diagnostics in oncology, and accelerating demand for decentralized point-of-care molecular testing.
For a deeper, data-driven view of Qiagen’s valuation and competitive positioning, you may find it useful to explore the analyst toolkit on ValueRay, where you can overlay these fundamentals with peer benchmarks and scenario analyses.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (405.4m TTM) > 0 and > 6% of Revenue (6% = 124.2m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -0.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 75.21% (prev 67.42%; Δ 7.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 657.7m > Net Income 405.4m (YES >=105%, WARN >=100%) |
| Net Debt (771.6m) to EBITDA (814.4m) ratio: 0.95 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (218.5m) change vs 12m ago -2.49% (target <= -2.0% for YES) |
| Gross Margin 63.14% (prev 48.33%; Δ 14.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 32.30% (prev 31.36%; Δ 0.94pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 15.80 (EBITDA TTM 814.4m / Interest Expense TTM 34.3m) >= 6 (WARN >= 3) |
Altman Z'' 4.26
| (A) 0.24 = (Total Current Assets 2.53b - Total Current Liabilities 973.4m) / Total Assets 6.55b |
| (B) 0.40 = Retained Earnings (Balance) 2.65b / Total Assets 6.55b |
| (C) 0.08 = EBIT TTM 541.2m / Avg Total Assets 6.41b |
| (D) 0.78 = Book Value of Equity 2.27b / Total Liabilities 2.90b |
| Total Rating: 4.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.26
| 1. Piotroski 7.0pt |
| 2. FCF Yield 4.46% |
| 3. FCF Margin 23.05% |
| 4. Debt/Equity 0.58 |
| 5. Debt/Ebitda 0.95 |
| 6. ROIC - WACC (= 3.50)% |
| 7. RoE 11.48% |
| 8. Rev. Trend -34.07% |
| 9. EPS Trend -33.73% |
What is the price of QGEN shares?
Over the past week, the price has changed by -1.40%, over one month by +6.61%, over three months by +0.09% and over the past year by +11.23%.
Is QGEN a buy, sell or hold?
- Strong Buy: 6
- Buy: 3
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the QGEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50.8 | 7.9% |
| Analysts Target Price | 50.8 | 7.9% |
| ValueRay Target Price | 47.7 | 1.2% |
QGEN Fundamental Data Overview December 03, 2025
P/E Trailing = 25.5892
P/E Forward = 17.3611
P/S = 4.9572
P/B = 2.8372
P/EG = 0.3274
Beta = 0.677
Revenue TTM = 2.07b USD
EBIT TTM = 541.2m USD
EBITDA TTM = 814.4m USD
Long Term Debt = 1.63b USD (from longTermDebt, last quarter)
Short Term Debt = 499.6m USD (from shortTermDebt, last quarter)
Debt = 2.13b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 771.6m USD (from netDebt column, last quarter)
Enterprise Value = 10.70b USD (10.27b + Debt 2.13b - CCE 1.69b)
Interest Coverage Ratio = 15.80 (Ebit TTM 541.2m / Interest Expense TTM 34.3m)
FCF Yield = 4.46% (FCF TTM 477.3m / Enterprise Value 10.70b)
FCF Margin = 23.05% (FCF TTM 477.3m / Revenue TTM 2.07b)
Net Margin = 19.58% (Net Income TTM 405.4m / Revenue TTM 2.07b)
Gross Margin = 63.14% ((Revenue TTM 2.07b - Cost of Revenue TTM 763.3m) / Revenue TTM)
Gross Margin QoQ = 62.20% (prev 62.65%)
Tobins Q-Ratio = 1.63 (Enterprise Value 10.70b / Total Assets 6.55b)
Interest Expense / Debt = 0.39% (Interest Expense 8.22m / Debt 2.13b)
Taxrate = 3.48% (4.68m / 134.7m)
NOPAT = 522.4m (EBIT 541.2m * (1 - 3.48%))
Current Ratio = 2.60 (Total Current Assets 2.53b / Total Current Liabilities 973.4m)
Debt / Equity = 0.58 (Debt 2.13b / totalStockholderEquity, last quarter 3.65b)
Debt / EBITDA = 0.95 (Net Debt 771.6m / EBITDA 814.4m)
Debt / FCF = 1.62 (Net Debt 771.6m / FCF TTM 477.3m)
Total Stockholder Equity = 3.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.19% (Net Income 405.4m / Total Assets 6.55b)
RoE = 11.48% (Net Income TTM 405.4m / Total Stockholder Equity 3.53b)
RoCE = 10.49% (EBIT 541.2m / Capital Employed (Equity 3.53b + L.T.Debt 1.63b))
RoIC = 10.19% (NOPAT 522.4m / Invested Capital 5.13b)
WACC = 6.69% (E(10.27b)/V(12.39b) * Re(8.0%) + D(2.13b)/V(12.39b) * Rd(0.39%) * (1-Tc(0.03)))
Discount Rate = 8.0% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -1.21%
[DCF Debug] Terminal Value 79.02% ; FCFE base≈470.2m ; Y1≈495.0m ; Y5≈582.1m
Fair Price DCF = 47.04 (DCF Value 10.20b / Shares Outstanding 216.8m; 5y FCF grow 5.74% → 3.0% )
EPS Correlation: -33.73 | EPS CAGR: -6.35% | SUE: 1.05 | # QB: 1
Revenue Correlation: -34.07 | Revenue CAGR: -2.36% | SUE: 1.67 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.58 | Chg30d=+0.006 | Revisions Net=-1 | Analysts=8
EPS next Year (2026-12-31): EPS=2.54 | Chg30d=-0.006 | Revisions Net=+1 | Growth EPS=+6.4% | Growth Revenue=+6.0%
Additional Sources for QGEN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle